The NSCLC Content Hub Channel
2023 Best of Lung: Targeted Therapies in Lung Cancer
NSCLC Content Hub
This video features a presentation at the Best of Lung 2023 conference. Jaime Schneider, MD discusses the latest advancements in targeted therapies for lung cancer. They highlight the…
Therapeutic Advances in Targeting HER2 Alterations in NSCLC & Remaining Challenges
NSCLC Content Hub
Dr. Nicolas Girard, MD, PhD, explores new treatments for advanced HER2-positive non-small cell lung cancer (NSCLC). Highlighting the challenges faced by this orphan patient group, he discusses the…
Recent Videos in NSCLC Content Hub Page 2
Molecular Testing Used for Patients With Non-Small Cell Lung Cancer
NSCLC Content Hub
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
Evaluating the Role of Molecular Testing in Lung Cancer
NSCLC Content Hub
Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before…
Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC
NSCLC Content Hub
In this video interview, Jonathan W. Goldman, MD, a health sciences clinical instructor in the Department of Medicine at the Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics…
Dr. Husain on Ongoing Research Evaluating Plasma-Based Testing in Lung Cancer
NSCLC Content Hub
In this video, Hatim Husain, MD, medical oncologist and associate professor of medicine for Moores Cancer Center at UCSD, explores how liquid biopsies are being incorporated into studies…
Nasser Hanna, MD, on Treatment for NSCLC Sans Mutations
NSCLC Content Hub
There has been an explosion of new data from targeted therapy studies since the 2017 publication of ASCO’s full clinical practice guidelines regarding systemic therapy for patients with…
Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC
NSCLC Content Hub
Terence T. Sio, MD, MS, associate professor of radiation oncology at the Mayo Clinic and specialist in both X-ray-based and proton radiotherapies, discusses study results comparing the efficacy…
Pembro Ups Survival in NSCLC: ‘Really Extraordinary’ Results
NSCLC Content Hub
Long-term data from the KEYNOTE-010 trial showed that 35% of over 1,000 patients with non-small cell lung cancer (NSCLC) who had progressed on chemotherapy and were then treated…
First-Line Cyramza in NSCLC Gets Split Decision From FDA Panel
NSCLC Content Hub
The Oncologic Drugs Advisory Committee (ODAC) voted 6–5 that combining ramucirumab combined with established first-line EGFR-directed therapy had a favorable risk-benefit profile for patients with metastatic EGFR-mutant non-small…
Managing ALK-Positive NSCLC Disease Progression
NSCLC Content Hub
In this double interview, Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, and Lyudmila A. Bazhenova, MD, of UC San Diego Health, provide insights into…
Dr. Mirhadi on Novel Radiation Technologies in NSCLC
NSCLC Content Hub
New techniques and technology advancements in the field of radiation oncology are the topics of discussion in this interview with Amin J. Mirhadi, MD, associate professor of radiation…